Background: Renal function impairment is associated with poor prognosis in the setting of ST-elevation myocardial infarction. Methods: We hypothesized that decreased glomerular filtration rate (GFR) was associated with poor short-and long-term prognosis in patients with non ST-elevation acute coronary syndromes (NSTE-ACS). Data were pooled from NSTE-ACS TIMI trials, and patients were divided in 3 groups: with normal (>=90 mL/min/1.73m 2 ,group 1, n=4952), mildly decreased (60-89 mL/min/1.73m 2 , group 2, n=6262) and moderately to severely decreased GFR (<60 mL/min/1.73m 2 , group 3, n=2093) on presentation.
decreased GFR (<60 mL/min/1.73m 2 , group 3, n=2093) on presentation. Results: Mortality increased stepwise with decreasing GFR: 1.27%, 2.11%, and 5.02% at 30 days and 2.47%, 3.79% and 9.53% at 6 months in groups 1, 2, and 3 respectively (p<0.0001 for both). The combination of TIMI risk score (TRS) tertiles and decreasing tertiles of GFR provided further mortality stratification with highest 6-month mortality rate (15.44%) in lowest GFR combined with highest TRS (figure). Furthermore, decreased GFR was associated with mortality independent of TRS (at 30 days, OR=1.41 in group 2, p=0.03; OR=3.11 in group 3, p<0.001). In addition, stroke incidence at 30-day increased with decreased GFR: 0.33%, 0.59% and 1.27 % in groups 1, 2, and 3 respectively (p<0.0001).
Conclusion:
In the setting of NSTE-ACS, impaired GFR is associated with increased 30-day and 6-month mortality independent of TRS, and is associated with increased stroke incidence at 30 days.
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Underachievement Methods: Among 2220 patients with non-ST elevation acute coronary syndromes, we examined the statin doses used in those receiving statins at the time of entry in the TAC-TICS-TIMI 18 trial, and their relationship to the measured low-density lipoprotein cholesterol (LDL-C) on admission.
Results: At study entry, 722 (33%) patients were on statins, of whom 372 had LDL-C measurements available: 132 (35%) were on atorvastatin, 126 (34%) on simvastatin, 58 (16%) on pravastatin, and 15% on other statins. The doses used are shown in the Figure. Only 17% and 36% of patients were treated with the 40 mg doses of pravastatin or simvastatin as used in clinical trials. Only 1% of patients were treated with 80mg atorvastatin.
At entry, only 47% of these patients had LDL-C <100 mg/dl. At 6 months, although more patients (1129, 51%) were on statins, the doses of statins used were not higher than those used at baseline. Background: Pre-treatment of pts with STEMI with abciximab already in the mobile intensive care unit (MICU) is believed to facilitate percutaneous coronary intervention (PCI) and improve outcome. Methods: We randomised 100 pts with STEMI (age <80 yrs, symptoms <6hrs) to receive weight adjusted abciximab at the scene (PTx, n=52) or at intervention in the cath lab (HTx, n=48). All pts received 500 mg aspirin and 70 U/kg heparin in the MICU. Results: Groups were balanced for sex (19% female), age (median 63 yrs), localisation of MI (39% anterior) and symptom duration to arrival of MICU (median 50 min). Median duration of symptoms until abciximab injection was 68 min in pts with PTx and 164 min with HTx. Symptom duration to 1st visualisation of infarct related artery was 142 min in pts with PTx and 152 min with HTx respectively. ST segment resolution after 60-90 min (before PCI with PTx) was < 30% in 39%, 30-70% in 37% and >70% in 24% of pts, compared to 56%, 14%, and 30% with HTx respectively. With PTx initial TIMI-flow 0/1 was present in 48%, and TIMI-flow 2/3 in 52%, compared to 52% and 48% with HTx respectively. Blush grade before intervention with PTx was 0/1 in 63%, and 2/3 in 37%, compared to 66% and 34% with HTx respectively. Stents were successfully placed in 93% of pts. TIMI-flow 3 was achieved in 88% of pts with PTx and 82% with HTx. None of the differences were significant. Results tended to be in favour of PTx in pts who were treated within the 1st hour after symptom onset independent of the time interval between start of treatment and 1st visualisation of IRA. One HTx-pt died on day 4 after prolonged resuscitation, two pts had major bleeds (1 PTx, 1HTx). Urgent CABG was performed in 7 pts (4 PTx, 3 HTx) until day 5. Until day 180, three pts with PTx had reinfarctions, two within 30 days, one during month 4. Ten pts had ischemia driven re-PCI of IRA (5 PTx, 5 HTx), three of these within the first 30 days after the index event.
Conclusion: Pre-hospital application of abciximab is safe and feasible. However, in some contrast to previous reports we found only minor advantages of abciximab pre-treatment in pts with STEMI and planned PCI. Also fast-track pre-hospital procedures in general may have added essentially to the excellent outcome of the pts. 
